Creating bioengineered organs for human transplant
Cell washing technique helps grow organs with patient-derived cells to minimize organ rejection
November 2, 2017
This material is available primarily for archival purposes. Telephone numbers or other contact information may be out of date; please see current contact information at media contacts.
More than 120,000 people are on the U.S. organ transplant waiting list. Miromatrix Medical, a small business funded by NSF, has developed a technology to create bioengineered organs for human transplant. The cell washing technique gently removes an organ's existing cells, but preserves the organ's structure. This creates a framework to grow a new organ from patient-derived cells, potentially minimizing rejection of the new organ. The Food and Drug Administration (FDA) approved Miromatrix's proprietary technique for use in a commercially available, biological mesh for hernia repair. The company's goal is to engineer replacement hearts and other organs. It is currently developing a cardiac patch to repair damage from heart disease.
Directorate for Engineering
#1142525 SBIR Phase I: A Perfusable, Revascularized, Cardiac-Derived Patch for the Treatment of Heart Disease
#1330956 SBIR Phase II: A Perfusable, Revascularized, Cardiac-Derived Patch for the Treatment of Heart Disease